INTRODUCTION
Kidney transplantation is the best form of treatment for patients with end-stage renal disease (ESRD) of any cause. Kidney transplant recipients (KTRs) experience survival benefits in all age groups have a better health-related quality of life and transplant is cost-effective compared to dialysis [1] [2] [3] . There have been significant improvements in early graft survival due to advances in immunosuppression and the overall medical care of transplant recipients. However, long-term graft survival has only had a modest improvement [4] [5] [6] . Allograft failure among transplanted kidney recipients is now the fourth leading cause of ESRD in the United States [7] . Studies from nearly a decade ago suggest that antibody-mediated rejection (ABMR) and disease recurrence are the most common causes of graft failure [7, 8] . However, the causes of "true" late kidney allograft failure remain unclear [9] . In this study, we explored the causes of graft failure based on time after transplant, causes of ESRD and induction immunosuppressive medication in the current era, which may allow providers to determine interventions to prevent poor outcomes.
MATERIALS AND METHODS

Study population and design
We study KTRs who were transplanted at the University of Wisconsin, and who had graft failure between January 1, 2006 and December 31, 2016 and transplanted between January 1, 1994 to December 31, 2016. We chose 2006 as a current era because at that time most of our clinical practice including histopathological reporting were protocolized. Patients were included if they underwent a kidney biopsy within one year prior to the graft failure. If they had multiple biopsies within one year prior to the graft failure, the biopsy closest to the graft failure was included in the analysis. Patients with primary graft dysfunction (defined as not having functional allograft and needing dialysis for at least 3 mo post-transplant or graft nephrectomy) or death with a functional graft were excluded from the study (Figure 1 ). This study was approved by the Health Sciences Institutional Review Board at the University of Wisconsin.
Data collection
We analyzed data on age, gender, race, re-transplant status, the cause of ESRD, type of transplant, induction immunosuppression, organ failure method before graft failure (re-transplant vs initiation of dialysis). In cases where a patient had multiple biopsy diagnoses, all diagnoses were also reported separately, although the primary diagnosis (first diagnosis) was used for the cause of graft failure. We divided the causes of graft failure based on the post-transplant interval divided into 2 years interval, based on the causes of ESRD and also the types of induction immunosuppressive medication.
Immunosuppression
Patients undergoing kidney transplant received induction immunosuppression with either a depleting (anti-thymocyte globulin, alemtuzumab or OKT3) or non-depleting (basiliximab or daclizumab) agent-based on immunological risk factors. Patients were typically maintained on a triple immunosuppressive regimen with a calcineurin inhibitor (CNI, usually tacrolimus), antiproliferative agent (usually mycophenolate mofetil or mycophenolic acid), and steroids. Some patients had early steroid withdrawal based on clinical judgment and the patient's request. Doses and drug levels were individually adjusted at physician discretion based on the patient's clinical condition, including infection, malignancy, and rejection. Patients were maintained on the same immunosuppressive medication until graft failure. However, if there was a feature of CNI toxicity on biopsy, then CNI trough goal was lowered or even discontinued based on physician discretion. Once the patient return on dialysis, immunosuppressive medication was tapered down and maintained only on low dose steroid. Switching to mTOR inhibitor among failing graft was not common practice.
Kidney allograft biopsy
The majority of the biopsies were performed for-cause, mainly for the unexplained rise in serum creatinine, concern for rejections, significant proteinuria, or the development of de novo donor-specific antibodies (DSA). Protocol biopsies were performed at months 3 and 12 for all patients with pre-transplant DSA, and 6-12 wk after treatment of rejection.
Rejection treatment
ABMR treatment protocols at our institution are based on both the severity of rejection and the time after transplant at which ABMR is diagnosed as described previously [10] . Briefly, for early rejection (within 3 mo post-transplant), treatment includes dexamethasone 100 mg bolus and taper, plasmapheresis (PP) 4-6 sessions, and intravenous immunoglobulin (IVIG) 100 mg/kg after each PP. Late rejection (> 3 mo post-transplant) is treated with dexamethasone 100 mg bolus and taper and IVIG 200 mg/kg every 2 wk × 3. Rituximab 375 mg/m 2 as a single dose is added based on clinical and laboratory characteristics. The treatment regimen for both smoldering and clinical rejection is the same at our institution.
Treatment of acute cellular rejection (ACR) is also based on Banff criteria and severity. Borderline and Banff stage I rejection is treated with steroid pulse. Banff II and III ACR are treated with steroid pulse and Thymoglobulin 6-10.5 mg/kg in 4 to 7 divided doses. In mixed rejection, steroid pulse, IVIG, Thymoglobulin 10.5 mg/kg ± rituximab are used.
Statistical analysis
Continuous data were compared using Student's t-test or the Wilcoxon rank-sum test, as appropriate, while categorical data were analyzed using Fisher's exact test or chisquare test. P values < 0.05 were considered statistically significant. All analyses were performed using the MedCalc Statistical Software version 16.4.3 (MedCalc Software bvba, Ostend, Belgium; https://www.medcalc.org; . 
RESULTS
Study population
A total of 654 patients had death-censored graft failure during the study period. Of these, 329 (50%) fulfilled our selection criteria and were included in the study.
Baseline characteristics
Out of the 329 KTRs included in the study, 127 (39%) were female and the majority were Caucasian (77%). Mean age at the time of transplant was 42.2 ± 13.7 years. Glomerulonephritis was the most common cause of ESRD and 33% were living KTRs. More than 50% had DSA around the time of graft failure. The mean interval from biopsy to graft failure was 106.5 ± 104.6 d (Table 1) .
Biopsy findings
Interstitial fibrosis and tubular atrophy (IFTA) was the most common biopsy finding in 53% of all failed grafts, followed by acute rejection (AR) in 43% and transplant glomerulopathy (TG) in 33%. Less common findings were acute tubular necrosis, arteriosclerosis, recurrence of disease, donor vascular disease and BK nephropathy (BKVN) (Figure 2 ).
Common causes of graft failure based on the primary diagnosis
AR was the most common cause of graft failure and accounted for 40% (32% ABMR or mixed rejection and 8% ACR) of all graft failure. TG (17%), IFTA (13%), disease recurrence (7%) including the recurrence of diabetic nephropathy and glomerular disease, and BKVN (5%) were the following common causes of graft failure. Other less common causes of graft failure were donor vascular disease, prolonged acute tubular necrosis, CNI toxicity, and renal infarction (18% total graft failures). Among patients with AR as a cause of graft failure, 74 % had human leukocyte antigen (HLA) DSA at time of a biopsy, while 17% did not have HLA DSA and in 9% HLA DSA was not tested (Figure 3 ).
Common causes of graft failure based on the cause of ESRD
We further analyzed the cause of graft failure based on the three most common causes of ESRD: Glomerulonephritis, diabetes, and hypertension. AR was significantly higher in the glomerulonephritis and hypertension group compared to diabetes, and acute tubular necrosis was higher in the hypertension group (Table 2) .
Common causes of graft failure based on the induction immunosuppressive medication
Patients were divided into two groups based on the induction immunosuppressive medication they received at time of transplant: Depleting agents (Anti-thymocyte globulin or alemtuzumab or OKT3) and non-depleting agents (basiliximab or daclizumab), which also included patients who received no or unknown induction. In the non-depleting group, TG was a significantly higher cause of graft failure compared to depleting agent group 48% vs 24% ( Table 3) .
Causes of graft failure according to time after transplant
AR, was the most common cause of graft failure in the early post-transplant period (within six years post-transplant) and accounted for 31% of total graft failures. (23% ABMR or mixed rejection and 8% ACR). There was a significant trend for graft failure due to rejection in the early post-transplant period (P = 0.001), while in the late posttransplant period, TG was the most common cause of graft failure (P ≤ 0.001). The incidence of graft failure due to AR was higher up to 6 years post-transplant, with TG being the most common cause after 6 years ( Figure 3) . A total of 101 (48% of 212) graft failures within six years post-transplant were due to AR compared to 31 (26% of 117) after six years post-transplant (P = 0.01). TG was the primary cause of graft failure in 9% of patients within the first six years compared to 32% after six years (P < 0.001) (Figure 4) . Rejection, TG, IFTA, and disease recurrence were evenly distributed as primary causes of graft failure after 10 years, each at approximately 20%-25%. Unsurprisingly, BKVN was more common in first 4 years post-transplant. The most common time for graft failure was within two years post-transplant (n = 117, 36%). Subsequently, approximately 10%-15% of grafts failed every two years: > 2-4 years (n = 51, 16%), > 4-6 years (n = 44, 13%), > 6-8 years (n = 35, 11%), > 8-10 years (n = 31, 9%) and > 10 years (n = 51, 16%). Among 56 (17%) patients with the primary diagnosis of TG as a cause of graft failure, 25 (45%) had at least one episode of ABMR in the past. Similarly, around the time of last biopsy ( ± 3 mo), HLA-DSA was present in 30 (54%), DSA was not detected in 13 (23%) of the patients, and in 23% DSA was not checked around the time of biopsy (Figures 4 and 5 ). 
DISCUSSION
In this study of the cause of graft failure among KTRs, we found that the primary cause of graft failure varies with time after transplantation. AR, mainly ABMR, was the most common cause of graft failure and accounted for 40% of graft failures, which peaked at 6 years post-transplant. After an AR, TG, one of the most specific histological findings of chronic ABMR [11] , accounted for 17% of graft failure, which occurred mainly after 6-7 years post-transplant and was the most common cause of graft failure and even surpassed AR as a cause of graft failure. With careful adjustment of CNI dosing and with close monitoring of trough level, CNI toxicity was not a prevalent cause of graft failure in our cohort, which was considered one of the common cause of graft failure in the past.
There has been a dramatic improvement in the rate of AR. The half-life of a standard criteria deceased donor kidney in the United States has increased by almost 50%, from 10.6 years in 1989 to 15.5 years in 2005, and a similar pattern was seen with living donor transplantation [5] . This change was paralleled by a dramatic decline in graft failure within the first-year post-transplant period. Unfortunately, deathcensored graft failure beyond the first year has remained unchanged since 1989 [12] . During this time, our understanding of rejection and management have evolved, and graft failure due to hyperacute rejection is very rare. With newer protocols, ACR rates have decreased to less than 10% in the first year [5] . In the current era, our focus is on the prevention and treatment of ABMR. Certain newer therapeutics are considered for ABMR treatment based on their mechanism of action, such as anti-CD20 antibodies (e.g., ofatumumab and ocrelizumab), anti-CD22 antibody (epratuzumab), agents targeting B cell activation (e.g., atacicept and belimumab), and Anti-C5 antibody (eculizumab) [13] [14] [15] , and others potentially in the investigational pipeline. Most of the work is being conducted in the fields of prevention and treatment of AR, and in time we may be able to effectively manage AR including acute ABMR. However, chronic changes and the lesser understood mechanisms of TG and IFTA may hinder our aim of prolonged graft survival.
TG has evolved as one of the histological features of chronic ABMR [16] . Overt TG is characterized histologically by glomerular basement membrane duplication in ≥ 1 of the capillary loops, mesangial expansion with or without mesangial hypercellularity, and mesangial cell interposition; glomerulitis can accompany these lesions [17] . The overall incidence of TG increases with time after transplant, occurring in approximately 20% by 5 years post-transplant [18, 19] . TG is rarely diagnosed clinically within the first year of transplant, as TG lags behind the initial histologic stages of the disease [18] . In one study, subclinical TG (with stable renal function) was diagnosed in a protocol biopsy at a rate of 2.8% in the first year, which increased to 11.5% by 5 years post-transplant [18] . TG with significant proteinuria (> 2.5 g/day) is associated with worse graft survival outcomes compared with those with less proteinuria [20] . In the biopsy, TG is usually accompanied with the features of chronic damage to the allograft parenchyma mainly as fibrous intimal thickening of arteries, arteriolar hyalinosis and segmental and/or global glomerulosclerosis, IFTA and sometimes failure of peritubular capillaries [16] . Among patients with TG and active ABMR, outcomes are even worse; in one large observational study, 76% of the recipients lost their graft with a median survival of 1.9 years after the diagnosis of chronic active ABMR [21] . Overall, TG is associated with poor long-term graft survival, as grafts with TG fail sooner than those without [22] . Much effort is being made to investigate therapeutic options for the treatment of TG. Cooper et al. , studied the effects of highdose IVIG in chronic ABMR and did not find any favorable outcomes. Nine of 20 treated patients in their study had a follow-up biopsy and only 4 had no histological progression [23] . Similarly, in a recent randomized double-blinded clinical trial, the addition of IVIG and rituximab was not useful in patients with TG [24] . IFTA is a final common pathway involving a number of independent and overlapping cellular and molecular pathways [25] . In a recent study, prior ACR was associated with inflammation within IFTA and presence of inflammation within IFTA was associated with accelerated IFTA, arterial hyperplasia and chronic glomerulopathy along with reduced renal function compared to those without inflammation [26] . There is no reliable way to differentiate the cause of IFTA based on the morphology alone, or immunohistochemistry and molecular techniques [27] . Tubular atrophy and interstitial fibrosis progress in parallel [28] . In one surveillance biopsy among 321 KTRs, interstitial fibrosis was present in 71% of the graft at two years [28] . To date, there is no consensus about the mechanism or treatment for IFTA but chronic immune rejection and inflammation is considered one of the mechanisms [29] . Also, immune cell-derived and locally active complement has been associated with the progression of chronic fibrosis [30] . These suggest that although not as strong association as with TG, IFTA could be related to an immune-derived mechanism leading to graft loss.
Calcineurin inhibitor toxicity, thrombotic microangiopathy, and other causes of graft loss each contributed to 5% or less to graft failure. Our observations have the limitations inherent in this type of study. As a single-center study, it may not be possible to generalize our results to other centers. We looked for the specific causes of graft failure based on the primary biopsy diagnosis, but the specific management based on the biopsy findings was beyond the scope of this study. Similarly, around 50% of our patient population were excluded due to no biopsy within one year prior to the graft failure and it was not possible to determine the histopathological characteristics of those patients. We also excluded the small number of patients with primary graft dysfunction to avoid any surgical and technical issues for graft failure.
In summary, AR is still the most common cause of early graft failure in the current era of immunosuppression. Most early graft failures within the first six years of transplant are related to AR and are in theory preventable. Similarly, more effective diagnostic, monitoring, and therapeutic strategies for TG and IFTA are needed to improve long-term graft survival. (14) 14 (20) 4 (11) Interstitial fibrosis and tubular atrophy 11 (11) 12 (17) 5 (14) BK nephropathy 3 (3) 7 (10) 2 (6) Acute tubular necrosis 1 (1) 5 (7) 3 (9) Recurrence 6 (6) 6 (8) 1 (3) Other 15 (15) 6 (8) 3 ( 
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Research background
Although, there have been significant improvements in early graft survival due to advances in immunosuppression and the overall medical care of transplant recipients. However, long-term graft survival has only had modest improvement. The causes of "true" late kidney allograft failure remain unclear.
Research motivation
In this study, we explored the causes of graft failure based on various histopathological findings after transplant in the current era, which may allow providers to determine interventions to prevent poor outcomes.
Research objectives
The main objectives, of this study, was to identify the common causes of death censored graft failure among kidney transplant recipients. Knowing the causes may help provider to intervene on time and prevent for the graft loss.
Research methods
This was a single-center, retrospective study among kidney transplant recipients who were transplanted at the University of Wisconsin, and who had graft failure between January 1, 2006 and December 31, 2016 and transplanted between January 1, 1994 to December 31, 2016 . Patients were included if they underwent a kidney biopsy within one year prior to the graft failure. We divided histopathological causes of graft failure based on the post-transplant interval divided into 2 years interval, based on the causes of ESRD and also the types of induction immunosuppressive medication. In cases where a patient had multiple biopsy diagnoses, all diagnoses were also reported separately, although the primary diagnosis (first diagnosis) was used for the cause of graft failure.
Research results
A total of 329 kidney transplant recipients fulfilled our selection criteria and were included in the study. The three most common biopsy findings were interstitial fibrosis and tubular atrophy (IFTA, 53%), acute rejection (AR, 43%) and transplant glomerulopathy (TG, 33%). Similarly, the three most common causes of graft failure based on the primary diagnosis were AR (40%), TG (17%), and IFTA (13%). Most grafts failed within two years of post-transplant (36%). Subsequently, approximately 10%-15% of grafts failed every two years: > 2-4 years (16%), > 4-6 years (13%), > 6-8 years (11%), > 8-10 years (9%) and > 10 years (16%). AR was the most common cause of graft failure in the first six years (48%), whereas TG was the most prevalent cause of graft failure after 6 years (32%) of transplant. Most early graft failures within the first six years of transplant are related to AR and are in theory preventable. Similarly, more effective diagnostic, monitoring, and therapeutic strategies for TG and IFTA are needed to improve long-term graft survival.
Research conclusions
In this study of the cause of graft failure among kidney transplant recipients, we found that the primary cause of graft failure varies with time after transplantation. AR, mainly antibodymediated rejection (ABMR), was the most common cause of graft failure and accounted for 40% of graft failures, which peaked at 6 years post-transplant. After an AR, TG, one of the most specific histological findings of chronic ABMR, accounted for 17% of graft failure, which occurred mainly after 6-7 years post-transplant and was the most common cause of graft failure and even surpassed AR as a cause of graft failure. Interestingly, calcineurin inhibitor toxicity was not a common cause of graft failure.
Research perspectives
Further studies in this field and specifically effective treatment of AR is needed to prolong the graft survival. Most of the work is being conducted in the fields of prevention and treatment of AR, and in time we may be able to effectively manage AR including acute ABMR. However, chronic changes and the lesser understood mechanisms of TG and IFTA may hinder our aim of prolonged graft survival and study should focus on the field of prevention or treatment of TG and IFTA.
